tyloxapol has been researched along with rosiglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jacinto, SM; Ljung, B; Oakes, ND; Thalén, PG | 1 |
| Adeli, K; Haidari, M; Lewis, GF; Naples, M; Szeto, L; Uffelman, K | 1 |
2 other study(ies) available for tyloxapol and rosiglitazone
| Article | Year |
|---|---|
Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Lipid Mobilization; Lipoproteins, VLDL; Liver; Male; Metabolic Clearance Rate; Muscle, Skeletal; Obesity; Oxidation-Reduction; Polyethylene Glycols; Postprandial Period; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2001 |
Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster.
Topics: Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Carrier Proteins; Cells, Cultured; Cricetinae; Enterocytes; Fasting; Insulin Resistance; Intestinal Mucosa; Intestines; Lipoproteins; Mesocricetus; Polyethylene Glycols; Postprandial Period; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |